In July 2005, Zynaxis Inc was acquired by SBIR firm Intracel Corporation. Zynaxis, Inc. is a biotechnology company engaged in the development and commercialization of new therapeutic drugs and cellular diagnostic products. In addition to the Zymmune system, the Company is developing other T and B cell monitoring kits, as well as products for evaluating hypercholesterolemia. In the therapeutic area, the Company is applying its Zyn-Linker™ technology to create more effective, site-specific formulations of approved drugs. Initial targets include cardiovascular disease, autoimmune disorders and cancer
